Vimarsana
Biggest News Aggregation in the World

Page 33 - Dave Fredrickson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dave Fredrickson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dave Fredrickson Today - Breaking & Trending Today

ENHERTU® Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Ad - Vimarsana News

ENHERTU® Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Ad

First HER2 directed medicine approved for patients with gastric cancer in a decadeTOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult pa...

Top UK Stocks to Watch: Babcock warns COVID-19 situation has 'worsened' - Vimarsana News

Top UK Stocks to Watch: Babcock warns COVID-19 situation has 'worsened'

Babcock shares dive as the virus weighs on its performance, AVEVA remains confident with its outlook, Indivior shares jump as it says it will beat expectations, and Meggitt says its recovery will take time.

AstraZeneca lung cancer drug gets nod for new dosing regimen in EU, UK - Vimarsana News

AstraZeneca lung cancer drug gets nod for new dosing regimen in EU, UK

AstraZeneca Plc said on Friday its cancer drug Imfinzi had been approved in Europe and Britain for a spaced-out regimen in a common type of lung cancer to help reduce the frequency of hospital visits while continuing treatment.

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Lynparza approved in Japan for three cancers - Vimarsana News

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Lynparza approved in Japan for three cancers

      AstraZeneca and MSD's Lynparza (olaparib) has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers.   The three approvals authorise Lynparza for: maintenance treatment after 1st-line chemotherapy containing bevacizumab (genetical recombination) for patients with homologous recombination repair deficient (HRD) ovarian cancer; the treatment of patients with BRCA gene-mutated (BRCAm) castrate-resistant prostate cancer with distant metastasis (mCRPC); and as maintenance treatment after platinum-based chemotherapy for patients with BRCAm cur...

AstraZeneca's Lynparza approved in Japan for three cancers - DirectorsTalk Interviews - Vimarsana News

AstraZeneca's Lynparza approved in Japan for three cancers - DirectorsTalk Interviews

AstraZeneca plc (LON:AZN) and MSD’s  Lynparza (olaparib) has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers. The three approvals authorise  Lynparza for: maintenance treatment after 1st-line chemotherapy containing bevacizumab (genetical recombination) for patients with homologous recombination repair deficient (HRD) ovarian cancer; the treatment of patients with BRCA gene-mutated (BRCAm) castrate-resistant prostate cancer with distant metastasis (mCRPC); and as maintenance treatment after platinum-based chemotherapy for patients with BRCAm...